PDF下载 ( 1950 KB)
Association between microRNA-155/SH2-containing inositol phosphatase-1 and cardiovascular events in patients with nonalcoholic fatty liver disease
-
摘要:
目的分析微小RNA-155（microRNA,miR-155）-155/含有SH2结构的5肌醇磷酸酶-1（SHIP-1）与非酒精性脂肪性肝病（NAFLD）患者发生心血管事件的相关性。方法选取2018年3月-2019年7月云南省第一人民医院收治的NAFLD患者104例,以及同期接受健康体检志愿者110例作为对照组。检测两组受试者BMI、血压及空腹血糖（FPG）、TC、TG、LDL-C、HDLC、ALT、AST、GGT、TBil等指标,采用荧光定量PCR法检测两组受试者外周血miR-155及SHIP-1 mRNA表达。计量资料2组间比较采用t检验;计数资料组间比较采用χ2检验;等级资料组间比较采用Kruskal-Wallis H秩和检验。相关性检验采用Pearson分析。采用受试者工作特征曲线（ROC曲线）分析miR-155/SHIP-1值对患者心血管事件的预测价值。结果 NAFLD组患者BMI、FPG、TC、TG、LDL-C、ALT、AST、GGT、TBil水平均明显高于对照组,HDL-C水平明显低于对照组,miR-155 mRNA相对表达量明显高于对照组,SHIP...
Abstract:Objective To investigate the association between microRNA-155( miR-155)/SH2-containing inositol phosphatase-1( SHIP-1) and cardiovascular events in patients with nonalcoholic fatty liver disease( NAFLD). Methods A total of 104 patients with NAFLD who were admitted to our hospital from March 2018 to July 2019 were enrolled as NAFLD group,and 110 healthy volunteers who underwent physical examination in our hospital during the same period of time were enrolled as control group. Related indices were measured,including body mass index( BMI),blood pressure,fasting plasma glucose( FPG),total cholesterol( TC),triglyceride( TG),low-density lipoprotein cholesterol( LDL-C),high-density lipoprotein cholesterol( HDL-C),alanine aminotransferase( ALT),aspartate aminotransferase( AST),gamma-glutamyl transpeptidase( GGT),and total bilirubin( TBil),and quantitative real-time PCR was used to measure the mRNA expression of miR-155 and SHIP-1 in peripheral blood. The t-test was used for comparison of continuous data between two groups,the chi-square test was used for comparison of categorical data between two groups,and the Kruskal-Wallis H test was used for comparison of ranked data between groups. A Pearson correlation analysis was performed,and the receiver operating characteristic( ROC) curve was used to investigate the value of miR-155/SHIP-1 ratio in predicting cardiovascular events. Results Compared with the control group,the NAFLD group had significantly higher levels of BMI,FPG,TC,TG,LDL-C,ALT,AST,GGT,and TBil and a significantly lower level of HDL-C,as well as significantly higher relative mRNA expression of miR-155,significantly lower relative mRNA expression of SHIP-1,and a significantly higher incidence rate of cardiovascular events( t = 6. 617,9. 323,6. 668,8. 633,4. 285,22. 099,24. 093,20. 438,12. 366,6. 515,18. 893,18. 411,and 29. 967,χ2= 10. 476,all P < 0. 01). The patients were divided into three groups according to miR-155/SHIP-1 ratio,there were significant differences between the three groups in BMI,FPG,TC,TG,LDL-C,HDL-C,ALT,AST,GGT,TBil,and incidence rate of cardiovascular events( H = 20. 923,7. 936,6. 256,16. 181,21. 572,8. 435,18. 912,22. 869,7. 665,18. 657,and 9. 701,all P < 0. 05). The miR-155/SHIP-1 ratio was significantly correlated with BMI,FPG,TC,TG,LDL-C,HDL-C,ALT,AST,GGT,and TBil( r = 0. 297,0. 317,0. 332,0. 327,0. 286,-0. 279,0. 334,0. 352,0. 342,and 0. 350,all P < 0. 001). The patients with cardiovascular events had a significantly higher miR-155/SHIP-1 ratio than those without cardiovascular events( 3. 642 ± 1. 082 vs 2. 237 ± 0. 703,t = 11. 104,P < 0. 05),and the miR-155/SHIP-1 ratio had an area under the ROC curve of 0. 902 in predicting cardiovascular events in patients with NAFLD. Conclusion Abnormal glycolipid metabolism and liver function in patients with NAFLD are closely associated with the expression of miR-155/SHIP-1,and miR-155/SHIP-1 ratio has a certain value in predicting cardiovascular events in patients with NAFLD.
-
全世界约有一半新诊断的肝细胞癌(hepatocellular cell carcinoma，HCC)病例发生在我国，其中HBV感染是主要危险因素，占全球HCC病例的50%~80%[1]。HBV通过多种机制在宿主细胞中持续存在，从而导致慢性HBV感染[2]，并且诱导HCC发生[3]。超过80%的HCC在肝硬化基础上发展，这表明肝硬化在肝癌前环境中起着重要作用[4]。因此慢性HBV感染和肝硬化是肝癌发生的高风险因素。由于缺乏明显的症状和有效的筛查策略，80%的HCC患者被诊断时已为中晚期，其中仅有30%~40%患者符合当前有效治疗方案的条件[5]，故在早期将慢性HBV感染、肝硬化与HCC区分诊断是延长患者生存期甚至根治HCC的关键。现急需一种检测方式能够在患有良性肝病的肝癌高危人群中早期筛查出HCC，从而降低病死率。影像学检查作为有效筛查方法被应用于临床，但是受限于设备以及检测人员。实验室检测则更能筛查大量人群，目前主要的早期实验室筛查方法为检测患者血清AFP，但单一指标检测的敏感度与特异度存在限制。考虑联合指标检测能够提高诊断效率，本文将探究AFP与GGT/AST联合检测在良性肝病和HCC区别诊断中发挥的作用，以期为临床诊断提供新的参考依据。
1. 资料与方法
1.1 研究对象
选取2019年1月15日—6月15日于本院诊治的慢性乙型肝炎患者(CHB组)、乙型肝炎肝硬化患者(LC组)、HBV相关HCC患者(HCC组)，另选取同期健康体检者作为对照(HC组)。纳入标准：(1)HCC组患者HBsAg为阳性且诊断完全符合《原发性肝癌诊疗规范(2017年版)》[6]; (2)HCC组、CHB组和LC组患者均为首次诊断，在接受治疗前收集生化指标; (3)临床资料完整。排除标准：(1)排除HCC之外的恶性肿瘤; (2)排除HBV以外的其他肝炎病毒感染; (3)排除患有严重糖尿病、甲状腺亢进以及心血管疾病等患者; (4)排除妊娠患者。研究对象均自愿参与本项研究。
1.2 研究方法
采集所有研究对象空腹6~8 h后的静脉血5 ml，以转速3500 r/min(离心半径=16 cm)离心5 min，分离血清后-80 ℃冷冻备用。采用Siemens公司ADVIACENTUAR XP全自动化学发光免疫分析仪及配套试剂盒检测血清AFP水平，参考区间为0~8.0 ng/ml。使用Siemens公司ADVIA2400全自动生化分析仪检测AST、ALT、GGT水平，参考区间分别为15~40、5~40、10~60 U/L。以上操作严格依据说明书进行，所有检测均在试剂盒说明书规定时间内完成，且严格遵守试验相关操作规程。
1.3 伦理学审查
本研究方案经由武汉大学人民医院临床研究伦理委员会审批，批号：WDRY2018-K047。
1.4 统计学方法
采用SPSS 23.0软件、GraphPad Prism 6.0和MedCalc 18.2.1对数据进行统计分析。正态分布计量资料以x±s表示，多组间比较采用方差分析，进一步两两比较采用LSD-t检验。偏态分布计量资料以M(P25~P75)表示，多组间比较采用Kruskal-Wallis H检验，进一步两两比较采用Nemenyi检验。计数资料组间比较采用χ2检验。通过二元logistic回归分析，计算出预测变量，并绘制AFP、GGT/AST以及预测变量单独或联合检测的受试者工作特征曲线(ROC曲线)，计算曲线下面积(AUC)及敏感度、特异度，采用Z检验对AUC进行比较。P＜0.05为差异有统计学意义。
2. 结果
2.1 一般资料
共纳入研究对象352例，其中HC组86例，男42例，女44例，年龄23~82岁，平均(55.90±15.19)岁; CHB组68例，男38例，女30例，年龄22~77岁，平均(51.40±10.59)岁，HBV DNA阳性50例; LC组69例，男34例，女35例，年龄28~79岁，平均(53.49±11.35)岁，HBV DNA阳性36例，Child-Pugh A级25例，B级32例，C级12例; HCC组129例，男70例，女59例，年龄24~78岁，平均(54.60±11.17)岁，HBV DNA阳性50例，Child-Pugh A级79例，B级41例，C级9例，BCLC分期A期21例，B期31例，C期77例。4组研究对象年龄(F=1.455，P=0.227)与性别分布(χ2=1.346，P=0.718)差异均无统计学意义。
2.2 各指标检测结果比较
HCC组与HC组、CHB组、LC组之间患者的AFP、GGT/AST、GGT比较差异均有统计学意义(P值均＜0.05)(表 1)。
表 1 各组AFP、GGT、AST及GGT/AST血清学水平比较组别 例数 AFP(ng/ml) GGT/AST GGT(U/L) AST(U/L) HC组 86 3.35(2.20~4.70) 0.98(0.71~1.36) 20.00(15.00~27.00) 21.00(18.00~24.00) CHB组 68 4.35(2.35~15.75) 0.82(0.46~1.25) 51.00(23.75~140.75)1) 61.00(34.25~125.00)1) LC组 69 8.60(2.70~54.20)1) 0.97(0.55~1.81) 69.00(27.00~113.00)1) 47.00(31.00~88.00)1) HCC组 129 157.10(9.90~6126.40)1)2)3) 2.00(1.19~3.11)1)2)3) 98.00(45.00~207.00)1)2)3) 46.00(29.00~88.00)1)2) H值 124.018 70.202 126.282 135.987 P值 ＜0.001 ＜0.001 ＜0.001 ＜0.001 注：与HC组比较，1)P＜0.05;与CHB组比较，2)P＜0.05;与LC组比较，3)P＜0.05。 2.3 ROC曲线分析AFP与GGT/AST单独或联合检测诊断HCC的价值
采用二元logistic回归分析得到不同组别之间两种指标的联合回归模型，然后进一步绘制其ROC曲线(图 1)，计算AUC(表 2)，结果显示，在HCC组与LC组、HCC组与HC组+CHB组+LC组、HCC组与CHB组+LC组中，AFP与GGT/AST联合诊断的AUC均显著高于AFP单独诊断的AUC(Z值分别为2.684、2.241、2.415，P值分别为0.007、0.025、0.016)。
图 1 AFP与GGT/AST单独或联合检测诊断HCC的ROC曲线注：a，HCC组与CHB组; b，HCC组与LC组; c，HCC组与HC组+CHB组+LC组; d，HCC组与CHB组+LC组。表 2 AFP与GGT/AST单独或联合检测在辅助HCC诊断中的价值分组 标志物 AUC 95%CI 敏感度(%) 特异度(%) P值 HCC组vs CHB组 AFP 0.803 0.742~0.864 72.9 72.1 ＜0.05 GGT/AST 0.789 0.717~0.861 67.4 83.8 ＜0.05 联合 0.846 0.790~0.910 79.8 77.9 ＜0.05 HCC组vs LC组 AFP 0.760 0.693~0.826 55.8 84.1 ＜0.05 GGT/AST 0.727 0.650~0.803 90.7 46.4 ＜0.05 联合 0.802 0.741~0.862 48.1 97.1 ＜0.05 HCC组vs HC组+CHB组+LC组 AFP 0.835 0.791~0.879 86.0 68.2 ＜0.05 GGT/AST 0.768 0.718~0.817 67.4 74.9 ＜0.05 联合 0.843 0.802~0.885 73.6 78.5 ＜0.05 HCC组vs CHB组+LC组 AFP 0.781 0.727~0.835 55.8 85.4 ＜0.05 GGT/AST 0.758 0.700~0.815 67.4 77.5 ＜0.05 联合 0.823 0.775~0.871 81.4 66.4 ＜0.05 3. 讨论
HCC的发生通常伴有前期的慢性HBV感染和肝硬化，在慢性HBV感染以及患有肝硬化的高危人群中，利用有效的筛查方式早期发现HCC至关重要，是患者可能获得根治的关键[7]。本文纳入352例研究对象，基于相关纳排标准将其分为4组，统计分析结果发现HCC组与HC组、CHB组、LC组AFP和GGT/AST比较，差异均有统计学意义(P值均＜0.05)，此结果与以往研究结果[8]相符。
AFP作为最早被发现的蛋白肿瘤标志物之一[9]，其可反映肝功能情况，因此广泛用于实验室检查。综合全球多种指南，AFP在我国可作为良好的血清学指标[10]，但其特异度低，易引起误判[11]。在CHB、LC患者中AFP水平也会升高，因此鉴别诊断HBV相关HCC患者时，AFP具有一定局限性，且部分HBV相关HCC患者的AFP水平并未达到筛查标准，因此容易漏查[12]。
GGT在哺乳动物组织中广泛分布，是一种质膜结合蛋白，血清中的GGT主要来源于肝胆系统[13]。已有研究[14]表明GGT通过诱导DNA损伤来促进肿瘤进展和不良预后，释放活性氧以激活与入侵相关的信号通路，与HCC发展关联密切。AST主要分布于肝细胞线粒体内，当肝脏严重病变坏死时，血清中AST水平会显著升高[15]，作为肝功能检查常用生化指标，GGT与AST在临床中应用广泛[16]。本研究计算GGT/AST比值并发现其单独或联合AFP时在HBV相关HCC的诊断中具有一定价值，且该指标计算简单，不用另增检验项目，便于在HCC诊断过程中应用。
本研究ROC曲线分析结果显示，在HCC组与LC组中，GGT/AST联合AFP后AUC明显提高，表明GGT/AST与AFP联合在鉴别HCC与LC时有良好的诊断效果; 在HCC组与HC组+CHB组+LC组以及CHB组+LC组分别区别诊断时，二者联合的AUC均明显高于AFP单独诊断的AUC，进一步说明GGT/AST联合AFP在鉴别HCC与良性肝病患者中有较好的诊断价值。
综上所述，本研究表明GGT/AST联合AFP在HBV相关HCC的临床诊断中具有一定价值，提高了AFP的单独诊断效率。由于本研究样本量较小，因此相关研究结果仍需未来增加样本量予以验证。
-
[1] SWEET PH,KHOO T,NGUYEN S. Nonalcoholic fatty liver disease[J]. Prim Care,2017,44(4):599-607. [2] WILD SH,WALKER JJ,MORLING JR,et al. Cardiovascular disease,cancer,and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission[J]. Diabetes Care,2018,41(2):341-347. [3] FRANCQUE SM,van der GRAAFF D,KWANTEN WJ. Nonalcoholic fatty liver disease and cardiovascular risk:Pathophysiological mechanisms and implications[J]. J Hepatol,2016,65(2):425-443. [4] BREA A,PUZO J. Non-alcoholic fatty liver disease and cardiovascular risk[J]. Int J Cardiol,2013,167(4):1109-1117. [5] TRIVEDI I,RINELLA ME. NAFLD and cardiovascular disease:Can the real association be determined?[J]. Curr Hepatol Rep,2014,13(2):130-141. [6] LISA W,SLACK FJ. miR-155 as a novel clinical target for hematological malignancies[J]. Carcinogenesis,2020,41(1):2-7. [7] SCHWIMMER JB,BEHLING C,ANGELES JE,et al. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease[J].Hepatology,2017,66(5):1474-1485. [8] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组．非酒精性脂肪性肝病诊疗指南[J]．临床肝胆病杂志，2010,26(2):120-124. [9] HUDERT CA,TZSCHTZSCH H,GUO J,et al. US time-harmonic elastography:Detection of liver fibrosis in adolescents with extreme obesity with nonalcoholic fatty liver disease[J].Radiology,2018,288(1):99-106. [10] PISETTA C,PELIZZARI G,PIGOZZI MG,et al. Non-alcoholic fatty liver disease and cardiovascular risk[J]. J Hypertens,2019,37:e304. [11] MORELLO E,SUTTI S,FOGLIA B,et al. Hypoxia-inducible factor 2αdrives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein[J].Hepatology,2018,67(6):2196-2214. [12] TARGHER G,DAY CP,BONORA E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J].New Engl J Med,2010,363(14):1341-1350. [13] SU L,ZHANG YW,WANG Z. Proliferation inhibition and proapoptotic effects of shikonin on human leukemia MV4-11 cells[J]. J Jilin Univ(Med Edit),2020,46(1):96-101.(in Chinese)苏龙，张云蔚，王卓．紫草素对人白血病MV4-11细胞的增殖抑制和促凋亡作用[J]．吉林大学学报(医学版)，2020,46(1):96-101. [14] ZHANG L,GAO XF,WANG YH. The expression of chemerin and the influence of sitagliptin on its expression in non-alcoholic fatty liver disease rats complicated with prediabetes[J].Natl Med J China,2018,98(30):2407-2413.(in Chinese)张莉，高旭峰，王玉环．非酒精性脂肪肝并糖尿病前期chemerin表达及西格列汀对其表达的影响[J]．中华医学杂志，2018,98(30):2407-2413. [15] STOKES CS,LAMMERT F,KRAWCZYK M. Short-term dietary interventions for the management of nonalcoholic fatty liver[J]. Curr Med Chem,2019,26(19):3483-3496. [16] HU MQ,XU YQ,ZHANG T,et al. Research advances in noninvasive diagnostic methods for nonalcoholic steatohepatitis[J]. J Clin Hepatol,2017,33(12):2288-2291.(in Chinese)胡梦琪，徐有青，张涛，等．非酒精性脂肪性肝炎的无创诊断方法[J]．临床肝胆病杂志，2017,33(12):2288-2291. [17] ESTES C,RAZAVI H,LOOMBA R,et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology,2018,67(1):123-133. [18] YOUNOSSI ZM. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:Implications for liver transplantation[J].Liver Transpl,2018,24(2):166-170. [19] CHEN B,LIN HX. Intervention of polyene phosphatidylcholine on mice with nonalcoholic fatty liver disease and its effect on hepatic zinc finger protein A20 expression[J]. Chin J Clin Pharmacol Ther,2018,34(11):1353-1356.(in Chinese)陈彬，林海雪．多烯磷脂酰胆碱对非酒精性脂肪肝小鼠的干预及其对肝锌指蛋白A20表达的影响[J]．中国临床药理学杂志，2018,34(11):1353-1356. [20] DING J,ZHANG B,WANG PJ,et al. Analysis on mechanisms and medication rules of herbal prescriptions for nonalcoholic fatty liver disease based on methods of data mining and biological information[J]. China J Chin Mater Med,2019,44(8):1689-1695.(in Chinese)丁静，张斌，王培劫，等．基于数据挖掘和生物信息分析探讨非酒精性脂肪肝用药规律及作用机制[J]．中国中药杂志，2019,44(8):1689-1695. 期刊类型引用(3)
1. 姚爱武，廖和壁，张璟. 血清AFP、AFP-L3与肝细胞癌经肝动脉化疗栓塞术后疗效的关系分析. 分子诊断与治疗杂志. 2023(04): 690-693+698 . 
百度学术2. 朱富平，刘红强，常清，冷伟业. miR-222-3p在乙型肝炎病毒相关肝细胞癌血清外泌体中的表达及临床意义. 局解手术学杂志. 2022(08): 702-708 . 百度学术3. 高武林，韦超，郭晓烨. 术前血清MMP-9水平对HBV相关肝细胞癌患者肝切除术后生存的预测作用. 东南大学学报(医学版). 2022(05): 652-659 . 百度学术其他类型引用(2)
-
下载:
百度学术
下载:
